This PGY2 residency is designed to develop competencies necessary for specialized practice in infectious diseases pharmacotherapy. The program is individualized to meet needs and interests of the resident. The University of Colorado Hospital (UCH) and the CU School of Pharmacy are part of the Anschutz Medical Campus of the University of Colorado. PGY2 residents will be involved in teaching programs of the school, including didactic and clerkship teaching of PharmD students and PGY1 residents, as well as medical/surgical residents and fellows. While the program focuses on enhancing clinical skills, a research project is required for successful completion of the residency. Additional clinical research opportunities are available. Upon completion of this residency, graduates will be prepared to practice as an infectious diseases pharmacotherapy specialist and serve as an antimicrobial stewardship pharmacist in either a community or academic environment.

PRACTICE SITES/ROTATIONS:
The inpatient and outpatient services of UCH provide the primary teaching sites for this program. Rotation sites may also include other hospitals in the Denver area offering unique learning experiences not available at the University of Colorado Hospital; examples include Denver Health Medical Center and Children’s Hospital Colorado.

Rotations are usually scheduled in 4-week increments. Required clinical rotations include: antimicrobial stewardship (1 month); general ID inpatient consult service (2 months); immunocompromised host ID consult service (2 months); HIV/AIDS & hepatitis (1 month); BMT/hematology (1 month), orthopedic surgical ID service/outpatient antimicrobial therapy (OPAT) [1 month], and longitudinal experiences in antimicrobial stewardship and teaching/academia. Residents will also have opportunities to receive training in basic microbiological techniques and laboratory processes. Possible elective rotations include: infectious diseases/antimicrobial stewardship at other affiliated hospitals; pediatric ID; adult cystic fibrosis; research; and others.

Completion of the Colorado Pharmacy Residency Teaching Certificate program is required if completion of a similar program has not already been accomplished during a PGY1 program. Limited staffing (160 hours, approximately one weekend/month) in the inpatient areas of UCH is expected of the PGY2 ID residents.

REQUIREMENTS: Doctor of Pharmacy Degree (ACPE accredited program) and PGY1 Pharmacy Residency

PRECEPTORS FOR REQUIRED LEARNING EXPERIENCES:
- Karrine Brade, PharmD Clinical Coordinator, Infectious Diseases/Antimicrobial Stewardship
- Michael Casias, PharmD Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship
- Madison Salam, PharmD Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship
- Robin Bricker-Ford, PharmD Clinical Specialist in Infectious Diseases, Hepatology and HIV/AIDS
- Thalia McCann, PharmD Clinical Specialist in Infectious Diseases, HIV/AIDS
- Jeff Kaiser, PharmD Clinical Specialist in BMT/Hematology/Oncology
- Megan Wong, PharmD Clinical Specialist in Orthopedic Surgery/Orthopedic ID
- Douglas Fish, PharmD Clinical Specialist in ID/Critical Care, Residency Program Director

BENEFITS: PGY2 resident salary is $65,000 per year (estimated 2024-25). Benefits include healthcare insurance, generous annual leave and sick day policies, and a travel/professional development stipend. Residents receive a faculty appointment as Clinical Instructor in the School of Pharmacy.

APPLICATION: Interested applicants meeting the above criteria should electronically submit a letter of intent, curriculum vitae, academic transcripts, and three letters of recommendation through ASHP’s Pharmacy Online Residency Centralized Application Service (PhORCAS). PhORCAS is the required method of applying for this program. Please visit our web site (https://pharmacy.cuanschutz.edu/academics/residencies/) or contact the Residency Program Director at doug.fish@cuanschutz.edu for additional information concerning the program or application process.

The deadline for receipt of all application materials is no later than January 2, 2024.
This residency site agrees that no person at this site will solicit, accept, or use any ranking-related information from any residency applicant.